



1645

PTO/SB/21 (05-03)

Approved for use through 04/30/2003. OMB 0651-0031
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

TRANSMITTAL FORM <i>(to be used for all correspondence after initial filing)</i>		Application Number 09/927,422
		Filing Date August 10, 2001
		First Named Inventor Gary VAN NEST
		Art Unit 1645
		Examiner Name N. Minnifield
Total Number of Pages in This Submission 3		Attorney Docket Number 377882001420

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached <input checked="" type="checkbox"/> Amendment/Reply (2 pages) <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s) <input type="checkbox"/> Extension of Time Request <input type="checkbox"/> Express Abandonment Request <input type="checkbox"/> Information Disclosure Statement <input type="checkbox"/> Certified Copy of Priority Document(s) <input type="checkbox"/> Response to Missing Parts/Incomplete Application <input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation Change of Correspondence Address <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund <input type="checkbox"/> CD, Number of CD(s) _____	<input type="checkbox"/> After Allowance Communication to Group <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): Return Postcard
Remarks Customer No. 25225		

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT	
Firm or Individual name MORRISON & FOERSTER LLP Karen Zachow - 46,332	
Signature 	
Date September 15, 2003	

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9-15-03

Signature:

(Michael Boyd)

RECEIVED
TECH CENTER 1600
SEP 24 2003
160012900


BEST AVAILABLE COPIES



16
Docket No.: 377882001420
(PATENT)

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as First Class Mail, in an envelope addressed to: Mail Stop Non-Fee Amendment, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450, on the date shown below.

Dated: 9-15-03

Signature: 

(Michael Boyd)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Gary VAN NEST, et al.

Application No.: 09/927,422

Group Art Unit: 1645

Filed: August 10, 2001

Examiner: N. Minnifield

For: BIODEGRADABLE IMMUNOMODULATORY
FORMULATIONS AND METHODS FOR USE
THEREOF

RECEIVED
SEP 24 2003
TECH CENTER 1600/2900

RESPONSE TO RESTRICTION REQUIREMENT

Mail Stop Non-Fee Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

This is in response to the Office Action mailed August 13, 2003 (Paper No. 15) which sets forth a restriction requirement for pending claims 1-84 in the above-identified application. A response to this action is due September 15, 2003 (September 13th being a Saturday). Accordingly, this response is timely filed.

Restriction has been required as between the following allegedly distinct groups of inventions:

Group I. Claims 1-23 and 48-84 drawn to IMP/MC complex, composition and kit; and

Group II. Claims 24-47 drawn to a method of modulating an immune response in an individual comprising administering an IMP/MP complex to an individual.

BEST AVAILABLE COPY